FutureFemHealth

FutureFemHealth

Home
Work with us / Advertise
CensHERship
FutureFemHealth Pro
Partners and contributors
Archive
About

August 2026

Amara Therapeutics completes recruitment of nearly 600 women in major overactive bladder trial
A 596-patient randomized trial will test whether an app-based treatment can improve overactive bladder symptoms and quality of life in women.
 • Anna O'Sullivan
What 2,000 pitch decks tell us about women’s health investing
Cross-Border Impact Ventures’ Annie Thériault on five years inside the women’s health investment pipeline.
 • Anna O'Sullivan
One year on: Jason Clark on what Women’s Health Horizons has learned — and what the sector needs next
FutureFemHealth caught up with the founder and CEO of Women’s Health Horizons
 • Anna O'Sullivan
💌 Issue 160: $30m for heavy menstrual bleeding | Rael PE investment | $284m period care deal | HPV home testing
+ lots more in the weekly briefing on the global women's health market
 • Anna O'Sullivan
Reimbursement has moved up the women’s health agenda. Here’s why.
Founders and investors are thinking about who pays much earlier.
 • Anna O'Sullivan
Women’s health companies urged to weigh in on US Medicare payment changes
Advocates say the industry needs to make its voice heard
 • Anna O'Sullivan
Channel Medsystems raises $30m to expand heavy menstrual bleeding treatment
US medtech will accelerate commercial rollout of its non-hormonal Cerene treatment
 • Anna O'Sullivan
💌 Issue 159: $275m osteoporosis bet | FemTech & the NHS | New menopause drug data | Fertility reimbursement
+ lots more in the weekly briefing on the global women's health market
 • Anna O'Sullivan
Largest study to date maps how female testosterone levels change with age
Findings show testosterone declines gradually with age - rather than dropping off around menopause
 • Anna O'Sullivan
© 2026 FutureFemHealth Ltd · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for great culture